T Yamashita
Overview
Explore the profile of T Yamashita including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
2041
Citations
15140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeniya T, Emori M, Tsuchie H, Teramoto A, Nagasawa H, Mizushima E, et al.
Acta Orthop Belg
. 2025 Jan;
90(4):731-737.
PMID: 39869877
Atypical lipomatous tumors/well-differentiated liposarcomas (ALT/WDLPS) are low-grade, slow-growing, and locally aggressive tumors. We investigated clinical outcomes and recurrence factors for ALT/WDLPS of the extremities. This is retrospective study across three...
2.
Andre F, Cortes J, Curigliano G, Modi S, Li W, Park Y, et al.
Ann Oncol
. 2024 Sep;
35(12):1169-1180.
PMID: 39241960
Background: This exploratory pooled analysis investigated the efficacy and safety of trastuzumab deruxtecan (T-DXd) versus comparator treatment in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer...
3.
Kobayashi M, Kida A, Asai J, Takatori H, Kakinoki K, Urabe T, et al.
J Gastroenterol Hepatol
. 2024 Apr;
39(10):1965-1966.
PMID: 38654572
No abstract available.
4.
Saura C, Modi S, Krop I, Park Y, Kim S, Tamura K, et al.
Ann Oncol
. 2023 Dec;
35(3):302-307.
PMID: 38092229
Background: Primary analysis of the multicenter, open-label, single-arm, phase II DESTINY-Breast01 trial (median follow-up 11.1 months) demonstrated durable antitumor activity with trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth...
5.
Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al.
J Am Soc Nephrol
. 2023 Mar;
18(3):663-669.
PMID: 37001014
No abstract available.
6.
Sakatani K, Oyama K, Hu L, Warisawa S, Yamashita T
Adv Exp Med Biol
. 2022 Dec;
1395:139-143.
PMID: 36527628
Background: Recent studies reported that vascular cognitive impairment in the elderly caused by arteriosclerosis plays an important role in cognitive disorders in both vascular dementia and Alzheimer's disease. In addition,...
7.
Atlas H, Safa N, Denis R, Garneau P, Marceau S, Lebel S, et al.
Can J Surg
. 2022 Apr;
53(4):S51-S104.
PMID: 35488396
No abstract available.
8.
Rugo H, OShaughnessy J, Boyle F, Toi M, Broom R, Blancas I, et al.
Ann Oncol
. 2022 Mar;
33(6):616-627.
PMID: 35337972
Background: In monarchE, abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high-risk, early breast cancer (EBC) demonstrated a clinically meaningful improvement in...
9.
Ishijima M, Nakamura T, Shimizu K, Hayashi K, Kikuchi H, Soen S, et al.
Osteoarthritis Cartilage
. 2022 Mar;
30(6):852-861.
PMID: 35331859
Objectives: We previously reported, based on a multicenter randomized-control study, that the efficacy of intra-articular injections of hyaluronic acid (IA-HA) was not inferior to that of oral non-steroidal anti-inflammatory drugs...
10.
Ueo H, Minoura I, Gamachi A, Doi T, Yamaguchi M, Yamashita T, et al.
Br J Surg
. 2021 Aug;
108(10):e340-e342.
PMID: 34428279
No abstract available.